Why are peptides so popular and in the news?
Most peptides sold online are not FDA approved, and proof in people is weak or missing.
By the Peptide Science Desk Editorial TeamFact-checked against FDA and official sources · Not yet reviewed by a licensed clinician. How we check facts
Live tracker: is the FDA peptide policy final yet?
Why are peptides so popular right now?
- GLP-1 drugs made people trust the word "peptide." Wegovy, Ozempic, Zepbound and Mounjaro are FDA-approved peptide drugs.
- Social media. CNBC wrote on October 24, 2026 that YouTube and Reddit are "full of talk about peptides."
- Big promises. People sell peptides for muscle, healing, skin, sleep and aging, but most of these claims are not proven.
- News from Washington. Leaders have talked in public about making some peptides easier to get.
Why are peptides in the news?
- On October 14, 2026, the White House budget office got an FDA plan called "Interim Access Policy for Compounding Using Certain Peptides." Its ID is RIN 0910-ZD94.
- The AP reported, citing 2 unnamed people, that it may let pharmacies make some peptides, like BPC-157, for a while.
- On October 20, Reuters reported that RFK Jr. said the goal is "a regulated marketplace."
- Groups met White House reviewers about the plan in October 2026. A meeting is not a decision.
- On October 28, 2026, HHS issued it. It covers BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon, made by licensed pharmacies with a prescription. It is interim, and it is not FDA approval.
What did the FDA advisers vote in July 2026?
- On July 23 and 24, 2026, outside FDA advisers met about 7 peptides that pharmacies want to make.
- The AP said they voted to loosen limits on 6 of the 7, including BPC-157. Reuters said they voted 7 to 6 against the sleep peptide emideltide (DSIP).
- The AP reported that FDA staff scientists said none had been studied enough.
- A vote is advice. The FDA makes the final call.
Are peptides legal now?
- Partly, for 6 peptides. Since October 28, 2026, HHS says it will not take action against licensed pharmacies that make BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon with a prescription, under strict interim rules. That is not FDA approval.
- FDA-approved peptide drugs are legal with a prescription.
- "Not FDA approved" does not always mean illegal. It depends on what the product is, who makes it, and how it is sold.
- Products labeled "research use only" are not medicine for people.
Do the popular peptides actually work?
- Some do. The GLP-1 drugs have big studies in people, and the FDA approved them.
- Many others do not have good proof. A 2026 review found only 30 people in all human studies of BPC-157.
- CNBC quoted Dr. Caleb Alexander of Johns Hopkins: these products lack "robust human studies on safety and effectiveness."
- We rate FDA status, proof and safety on their own for each peptide. Check any peptide with our free tool.
Why are peptides banned in sports?
- WADA, the world anti-doping group, bans many peptides.
- From January 1, 2027, its list names "peptides" in its rule for drugs not approved anywhere.
- Athletes can fail a test even if the product was sold as a supplement.
What should I do before trying a peptide?
- Talk to a doctor or pharmacist. Ask if it is FDA approved for what you want.
- Do not buy from sites that say "research use only" or "not for human use."
- Watch our policy tracker. We update it when the FDA plan changes.
The numbers in charts
Weight loss in big obesity drug trials
% of starting body weight lost, drug vs placebo (fake shot)
Tirzepatide 15 mg (Zepbound)SURMOUNT-1 · 2,539 adults · 72 weeks
Semaglutide 2.4 mg (Wegovy)STEP 1 · 1,961 adults · 68 weeks
Liraglutide 3.0 mg (Saxenda)SCALE · 3,731 adults · 56 weeks
Different trials, different people: not a head-to-head comparison.
Show the numbers as a table
| Trial | Drug | Placebo |
|---|---|---|
| Tirzepatide 15 mg (Zepbound) SURMOUNT-1 · 2,539 adults · 72 weeks | −20.9% | −3.1% |
| Semaglutide 2.4 mg (Wegovy) STEP 1 · 1,961 adults · 68 weeks | −14.9% | −2.4% |
| Liraglutide 3.0 mg (Saxenda) SCALE · 3,731 adults · 56 weeks | −7.4% | −3.0% |
Newer weight-loss drugs still in testing
Change in body weight, drug vs placebo. A minus sign means weight lost
Retatrutide 12 mgIn testingTRIUMPH-1 · 2,339 adults · 80 weeks
CagriSema (cagrilintide + semaglutide)In testingREDEFINE 1 · 3,417 adults · 68 weeks
Mazdutide 6 mgIn testingGLORY-1 · 610 adults in China · 48 weeks
Survodutide 6.0 mgIn testingSYNCHRONIZE-1 · 725 adults · 76 weeks
Different trials, different people: not a head-to-head comparison. None of these is FDA approved.
Show the numbers as a table
| Trial | Drug | Placebo |
|---|---|---|
| Retatrutide 12 mg (In testing) TRIUMPH-1 · 2,339 adults · 80 weeks | −25.0% | −3.9% |
| CagriSema (cagrilintide + semaglutide) (In testing) REDEFINE 1 · 3,417 adults · 68 weeks | −20.4% | −3.0% |
| Mazdutide 6 mg (In testing) GLORY-1 · 610 adults in China · 48 weeks | −14.0% | +0.3% |
| Survodutide 6.0 mg (In testing) SYNCHRONIZE-1 · 725 adults · 76 weeks | −13.0% | −5.4% |
How many people each peptide was tested in
Biggest study in people we list for each one (log scale, so small numbers still show)
GLP-1: Wegovy / Ozempic (semaglutide)FDA approvedSELECT heart trial
GLP-1: Trulicity (dulaglutide)FDA approvedREWIND heart trial
GLP-1: Saxenda / Victoza (liraglutide)FDA approvedSCALE
Cagrilintide (part of CagriSema)In testingREDEFINE 1 (with semaglutide)
GLP-1 pill: Foundayo (orforglipron)FDA approvedATTAIN-1 · not a peptide
GLP-1: Zepbound / Mounjaro (tirzepatide)FDA approvedSURMOUNT-1
Tymlos (abaloparatide)FDA approvedACTIVE
GLP-1: RetatrutideIn testingTRIUMPH-1
Forteo (teriparatide)FDA approvedFracture trial
Vyleesi (bremelanotide, PT-141)FDA approvedRECONNECT (2 trials)
Thymosin alpha-1Not FDA approvedTESTS sepsis trial · no benefit
Egrifta (tesamorelin)FDA approvedBelly fat trial
IpamorelinNot FDA approvedPhase 2 (gut, after surgery)
SemaxNot FDA approvedNot randomized
SelankNot FDA approvedSmall randomized study
BPC-157Not FDA approvedAll 3 small studies added up
GHK-CuNot FDA approvedSkin product trial
TB-500Not FDA approvedNo study of TB-500 itself
KPVNot FDA approvedMice only
MOTS-cNot FDA approvedMice only
AOD-9604Not FDA approvedRats only
The popular online peptides were tested in tens of people, or none. The approved drugs were tested in thousands.
Show the numbers as a table
| Peptide | People in the study |
|---|---|
| GLP-1: Wegovy / Ozempic (semaglutide) (FDA approved) SELECT heart trial | 17,604 people |
| GLP-1: Trulicity (dulaglutide) (FDA approved) REWIND heart trial | 9,901 people |
| GLP-1: Saxenda / Victoza (liraglutide) (FDA approved) SCALE | 3,731 people |
| Cagrilintide (part of CagriSema) (In testing) REDEFINE 1 (with semaglutide) | 3,417 people |
| GLP-1 pill: Foundayo (orforglipron) (FDA approved) ATTAIN-1 · not a peptide | 3,127 people |
| GLP-1: Zepbound / Mounjaro (tirzepatide) (FDA approved) SURMOUNT-1 | 2,539 people |
| Tymlos (abaloparatide) (FDA approved) ACTIVE | 2,463 people |
| GLP-1: Retatrutide (In testing) TRIUMPH-1 | 2,339 people |
| Forteo (teriparatide) (FDA approved) Fracture trial | 1,637 people |
| Vyleesi (bremelanotide, PT-141) (FDA approved) RECONNECT (2 trials) | 1,267 people |
| Thymosin alpha-1 (Not FDA approved) TESTS sepsis trial · no benefit | 1,106 people |
| Egrifta (tesamorelin) (FDA approved) Belly fat trial | 412 people |
| Ipamorelin (Not FDA approved) Phase 2 (gut, after surgery) | 114 people |
| Semax (Not FDA approved) Not randomized | 110 people |
| Selank (Not FDA approved) Small randomized study | 70 people |
| BPC-157 (Not FDA approved) All 3 small studies added up | 30 people |
| GHK-Cu (Not FDA approved) Skin product trial | 13 people |
| TB-500 (Not FDA approved) No study of TB-500 itself | 0 people |
| KPV (Not FDA approved) Mice only | 0 people |
| MOTS-c (Not FDA approved) Mice only | 0 people |
| AOD-9604 (Not FDA approved) Rats only | 0 people |
Hype vs what is known
| What people hear | What the records show | |
|---|---|---|
| GLP-1 drugs | Peptides that cause weight loss | FDA approved, with big studies in people |
| BPC-157 | Heals anything | Not FDA approved; 30 people in all human studies |
| "Peptides are legal now" | The FDA lifted the ban | Interim HHS policy since Oct 28, 2026 for 6 pharmacy-made peptides; not FDA approval |
| Safety | Natural, so safe | FDA lists safety concerns for several peptides |
FAQ
Why are peptides so expensive?
Approved peptide drugs are brand-name medicines. Prices depend on the drug, the dose and insurance. See our insurance guide for real price sources.
Did RFK Jr. legalize peptides?
No. He has spoken about a "regulated marketplace." On October 28, 2026, his department (HHS) issued an interim policy for 6 peptides made by licensed pharmacies with a prescription. That is not FDA approval, and it does not cover "research use only" products.
Is Hims selling peptides?
Reuters reported on October 15, 2026 that Hims & Hers said it plans to offer peptides if the rules allow. Hims was on the White House meeting list for October 23.
Are peptides a fad?
Some are proven drugs, like GLP-1s. Many others are popular without good proof in people.
When will the FDA peptide plan be final?
HHS issued an interim policy on October 28, 2026. It lasts until the FDA deals with each peptide in a final rule. No date for that rule is public. Our tracker checks it often.
Related pages
- GLP-1: what it is, drugs list and side effectsGLP-1 guide
- GLP-1: Wegovy / Ozempic (semaglutide)FDA approved · Proof: Strong
- GLP-1: Zepbound / Mounjaro (tirzepatide)FDA approved · Proof: Strong
- BPC-157Not approved · Proof: Early
- TB-500Not approved · Proof: Animal or lab only
- GHK-CuNot approved · Proof: Early
- GLP-1: RetatrutideIn testing · Proof: Strong
- What Are Peptides?Guide
- Do peptides really work? The honest answerGuide
- Are Peptides Safe? What to Know FirstGuide
- Hims peptides: what they plan to sell and whenGuide
- FDA peptide policy trackerTool
- Is my peptide FDA approved?Tool
- Do peptides show up on a drug test?Tool
- Compare GLP-1: Wegovy / Ozempic vs GLP-1: Zepbound / MounjaroComparison tool
We never share doses or tell you where to buy. Always ask your doctor. Print our doctor questions sheet.
Sources
- Reginfo.gov: Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), pending EO 12866 review (checked Oct 25, 2026)
- AP via NBC News: Trump administration advances plan for peptide drugs (Oct 16, 2026)
- Reuters via Yahoo: US FDA takes step to change peptide compounding policy (Oct 15, 2026)
- Reuters via Yahoo: Kennedy says Trump administration aims for regulated market for peptides (Oct 20, 2026)
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
- CNBC Make It: Fact vs. fiction: Doctors share whether peptides are safe and effective (Oct 24, 2026)
- PubMed: Poolton et al., Human evidence for BPC-157: a systematic review, Acta Orthop Belg 2026
- DailyMed (FDA label): Wegovy (semaglutide) prescribing information
- DailyMed (FDA label): Zepbound (tirzepatide) prescribing information
- FDA: Bulk drug substances that may present significant safety risks (Category 2 and withdrawn list)
- WADA: 2027 List summary of changes ("peptides" added to S0)
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Oct 28, 2026)
- Federal Register (public inspection): FR Doc. 2026-22192, HHS peptide compounding policy